DK3206692T3 - Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister - Google Patents
Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister Download PDFInfo
- Publication number
- DK3206692T3 DK3206692T3 DK15851238.4T DK15851238T DK3206692T3 DK 3206692 T3 DK3206692 T3 DK 3206692T3 DK 15851238 T DK15851238 T DK 15851238T DK 3206692 T3 DK3206692 T3 DK 3206692T3
- Authority
- DK
- Denmark
- Prior art keywords
- glucocorticoid
- treatment
- receptor antagonists
- liver disease
- fatty liver
- Prior art date
Links
- 229940083712 aldosterone antagonist Drugs 0.000 title 1
- 208000010706 fatty liver disease Diseases 0.000 title 1
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 title 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3206692T3 true DK3206692T3 (da) | 2024-04-29 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15851238.4T DK3206692T3 (da) | 2014-10-15 | 2015-10-14 | Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister |
Country Status (22)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3206692B1 (en) | 2014-10-15 | 2024-04-03 | Corcept Therapeutics Incorporated | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| WO2019236487A1 (en) * | 2018-06-04 | 2019-12-12 | Corcept Therapeutics Incorporated | Pyrimidine cyclohexenyl glucocorticoid receptor modulators |
| KR20210153056A (ko) | 2019-03-18 | 2021-12-16 | 리네트 케이. 니만 | 인슐린 감수성 개선 방법 |
| PH12022553008A1 (en) | 2020-05-06 | 2024-03-04 | Corcept Therapeutics Inc | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| MX2022013804A (es) | 2020-05-06 | 2022-11-30 | Corcept Therapeutics Inc | Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides. |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| EP4263508A4 (en) * | 2020-12-21 | 2024-11-27 | Corcept Therapeutics Incorporated | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| WO2022235647A1 (en) * | 2021-05-05 | 2022-11-10 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| JP2006508042A (ja) | 2002-07-18 | 2006-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体の修飾物質および方法 |
| EP1883624B1 (en) | 2005-05-18 | 2010-04-07 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| KR20080065617A (ko) * | 2005-09-19 | 2008-07-14 | 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 | 글루코코티코이드 수용체 발현의 조절 |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| EP2032134B1 (en) | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| JP2010523667A (ja) * | 2007-04-13 | 2010-07-15 | シェーリング コーポレイション | ピリミジンジオン誘導体およびその使用方法 |
| WO2009155481A1 (en) | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| CN103596431B (zh) | 2011-03-18 | 2016-06-22 | 科赛普特治疗公司 | 嘧啶环己基糖皮质激素受体调节剂 |
| EP3206692B1 (en) | 2014-10-15 | 2024-04-03 | Corcept Therapeutics Incorporated | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283761A (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| DK3206692T3 (da) | Behandling af fedtleversygdom med glucocorticoid- og mineralcorticoid-receptorantagonister | |
| IL264607A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| IL262041A (en) | Chimeric receptors and methods of use thereof | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| EP4212536C0 (en) | BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE | |
| PL3353210T3 (pl) | Przeciwciała anty-TIGIT i sposoby stosowania | |
| CL2016002462A1 (es) | Anticuerpos anti-ox40 y métodos de uso | |
| IL249092A0 (en) | Anti-gitr antibodies and methods of use thereof | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| LT3295951T (lt) | Anti-pvrig antikūnai ir naudojimo būdai | |
| PT3548033T (pt) | Compostos e respectivos métodos de utilização | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| IL251505A0 (en) | Neuroactive compounds and methods of use thereof | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| BR112016020830A2 (pt) | composição de poliolefina heterofásica modificada e método de preparação | |
| PT3160964T (pt) | Moduladores dos receptores de arilo e métodos de fabrico e utilização dos mesmos | |
| BR112016020889A2 (pt) | variantes de hppd e métodos de uso | |
| DK3280710T3 (da) | Fremgangsmåde til fremstilling af androgenreceptorantagonister og mellemprodukter deraf | |
| DK3166911T3 (da) | Inkorporering af biologiske midler i gødning | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister | |
| EP3398262A4 (en) | MICRO-OUTER CHARACTERIZATION AND SELECTION | |
| DK3250600T3 (da) | Behandling af autoimmune lidelser med cd154-antistoffer | |
| IL249582B (en) | Use of materials incorporating microparticles for avoiding the proliferation of contaminants |